GLP ‐1 Receptor Agonist–Based Prandial Insulin De‐Intensification in Outpatients With Type 2 Diabetes Receiving Basal–Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Pooled result · HbA1c changeResult — go to the resultMD −0.08 percentage points 95% CI −0.28 to 0.12Authors' conclusion
In adults with type 2 diabetes receiving established BBI/MDI therapy, GLP-1RA-based prandial insulin de-intensification was associated with maintenance of short-term glycaemic control while reducing body weight and total daily insulin requirements. A potential reduction in hypoglycaemia remains uncertain.
Study context
- Population
- Adult outpatients with T2D receiving established BBI/multiple daily injections (MDI) at randomisation
- Participants
- 1,332 outpatients7 RCTs
- Comparison
- GLP-1 RA-based prandial insulin de-intensification vs continued BBI/MDI
- Outcome
- Change in HbA1c
Pooled result
HbA1c change
MD
−0.08 percentage points
95% CI −0.28 to 0.12
P = 0.391
GLP-1 RA-based de-intensificationvs Continued BBI/MDI
MD −0.08 percentage points (95% CI −0.28 to 0.12); P = 0.391
As reported in the abstract
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| At least one hypoglycaemic event | 0.76 (0.66–0.87) | P = 0.007 | |
| 0.512Relative risk (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
GLP ‐1 Receptor Agonist–Based Prandial Insulin De‐Intensification in Outpatients With Type 2 Diabetes Receiving Basal–Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Diabetes Obes Metab. Published 14 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →